ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 4 for:    Vielight | Recruiting, Not yet recruiting Studies
Previous Study | Return to List | Next Study

Vielight Neuro RX Gamma - Feasibility Pilot

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03328195
Recruitment Status : Recruiting
First Posted : November 1, 2017
Last Update Posted : May 7, 2018
Sponsor:
Information provided by (Responsible Party):
Vielight Inc.

Brief Summary:
This study tests the effects of the Neuro RX Gamma on the cognitive and behavioral functioning of subjects with moderate-to-severe Alzheimer's Disease. The Neuro RX Gamma uses non-invasive near-infrared energy delivered to the brain in daily treatment sessions at home.

Condition or disease Intervention/treatment Phase
Alzheimer Disease Device: Neuro RX Gamma Device: Sham Not Applicable

Detailed Description:

The Neuro RX Gamma system is a headset which emits near-infrared energy through diodes placed on the scalp and inside a nostril.

A potential participant will undergo screening procedures to confirm eligibility to participate in the study, followed by randomization procedure to one of the study groups - treatment or sham (placebo). A dedicated caregiver will apply the device to the subject for 20 minute daily sessions at home, 6 days a week for a total of 12 weeks. The subject and caregiver will be required to return to the clinic for follow-up assessments after 3, 6 and 12 weeks of treatment.

40 patients will be enrolled in 2 clinical sites in Ontario, Canada.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Pilot Study Evaluating the Feasibility, Safety, and Efficacy of the Vielight Neuro RX Gamma Device for the Treatment of Moderate-to-severe Alzheimer's Disease
Actual Study Start Date : December 4, 2017
Estimated Primary Completion Date : June 2018
Estimated Study Completion Date : June 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Neuro RX Gamma
Neuro RX Gamma device delivering near infra-red light through four diodes positioned over the scalp and one positioned inside the nostril.
Device: Neuro RX Gamma
Twenty minute treatment, six days per week for 12 weeks

Sham Comparator: Sham light therapy
Sham Neuro RX Gamma device having the same appearance and sound as the Neuro RX Gamma device but does not emit the near-infrared light.
Device: Sham
Twenty minutes, six days per week for 12 weeks with sham device




Primary Outcome Measures :
  1. Change in the Severe Impairment Battery (SIB) score - An assessment of Severe Dementia in the elderly. [ Time Frame: Baseline to Week 12 ]
    The SIB evaluates cognitive abilities in severely impaired individuals. This scale covers social interaction, memory, orientation, language, attention, praxis, visuospatial ability, construction and orientation to name. There are 40 items and the SIB score ranges from 0-100. Individuals who score less than 63 on the SIB are rated as very severely impaired.


Secondary Outcome Measures :
  1. Device safety according to the number of device-related adverse events [ Time Frame: Baseline to Week 12 ]
    Subjects will be monitored for clinical evidence of device-related adverse events throughout the study.

  2. Change in the Severe Impairment Battery score - An assessment of Severe Dementia in the elderly. [ Time Frame: Baseline to Week 3 ]
    The SIB evaluates cognitive abilities in severely impaired individuals. This scale covers social interaction, memory, orientation, language, attention, praxis, visuospatial ability, construction and orientation to name. There are 40 items and the SIB score ranges from 0-100. Individuals who score less than 63 on the SIB are rated as very severely impaired.

  3. Change in the Severe Impairment Battery score - An assessment of Severe Dementia in the elderly. [ Time Frame: Baseline to Week 6 ]
    The SIB evaluates cognitive abilities in severely impaired individuals. This scale covers social interaction, memory, orientation, language, attention, praxis, visuospatial ability, construction and orientation to name. There are 40 items and the SIB score ranges from 0-100. Individuals who score less than 63 on the SIB are rated as very severely impaired.

  4. Change in the Alzheimer's Disease Cooperative Study - Activities of Daily Living for Severe Alzheimer's Disease (ADL SAD) score [ Time Frame: Baseline to Week 3 ]
    The ADL SAD assesses the performance of activities of daily living by patients with Alzheimer's disease. The assessment includes 19 questions. The score for each question ranges as follows: questions 1 - 5, 0 - 15; questions 6 - 8, 0 - 13; questions 9 - 12, 0 - 12; questions 13 - 15, 0 - 10 and questions 16 - 19, 0 - 4. Subscales will be summed to compute the total score. The total score ranges from 0 - 54 with higher scores indicating less functional impairment and greater competence.

  5. Change in the Alzheimer's Disease Cooperative Study - Activities of Daily Living for Severe Alzheimer's Disease (ADL SAD) score [ Time Frame: Baseline to Week 6 ]
    The ADL SAD assesses the performance of activities of daily living by patients with Alzheimer's disease. The assessment includes 19 questions. The score for each question ranges as follows: questions 1 - 5, 0 - 15; questions 6 - 8, 0 - 13; questions 9 - 12, 0 - 12; questions 13 - 15, 0 - 10 and questions 16 - 19, 0 - 4. Subscales will be summed to compute the total score. The total score ranges from 0 - 54 with higher scores indicating less functional impairment and greater competence.

  6. Change in the Alzheimer's Disease Cooperative Study - Activities of Daily Living for Severe Alzheimer's Disease (ADL SAD) score [ Time Frame: Baseline to Week 12 ]
    The ADL SAD assesses the performance of activities of daily living by patients with Alzheimer's disease. The assessment includes 19 questions. The score for each question ranges as follows: questions 1 - 5, 0 - 15; questions 6 - 8, 0 - 13; questions 9 - 12, 0 - 12; questions 13 - 15, 0 - 10 and questions 16 - 19, 0 - 4. Subscales will be summed to compute the total score. The total score ranges from 0 - 54 with higher scores indicating less functional impairment and greater competence.

  7. Change in the Neuropsychiatric Inventory (NPI) score which assesses behavioral changes in neurologic illnesses based on a standardized caregiver interview. [ Time Frame: Baseline to Week 3 ]
    The NPI assesses the frequency, severity and level of distress caused by 12 common dementia-related behaviors (delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, sleep and appetite/eating).

  8. Change in the Neuropsychiatric Inventory (NPI) score which assesses behavioral changes in neurologic illnesses based on a standardized caregiver interview. [ Time Frame: Baseline to Week 6 ]
    The NPI assesses the frequency, severity and level of distress caused by 12 common dementia-related behaviors (delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, sleep and appetite/eating).

  9. Change in the Neuropsychiatric Inventory (NPI) score which assesses behavioral changes in neurologic illnesses based on a standardized caregiver interview. [ Time Frame: Baseline to Week 12 ]
    The NPI assesses the frequency, severity and level of distress caused by 12 common dementia-related behaviors (delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, sleep and appetite/eating).

  10. Change in the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS CGIC) score. [ Time Frame: Baseline to Week 3 ]
    The ADCS CGIC gives the Clinician's assessment of the patient's response to the treatment. It is intended to be used as a measure of clinically meaningful change. The ADCS-CGIC focuses on clinicians' observations of change in the patient's cognitive, functional, and behavioral performance since the beginning of a trial. It relies on both direct examination of the patient and interview of the caregiver. Scored as marked/moderate/minimal improvement or worsening or no change.

  11. Change in the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS CGIC) score. [ Time Frame: Baseline to Week 6 ]
    The ADCS CGIC gives the Clinician's assessment of the patient's response to the treatment. It is intended to be used as a measure of clinically meaningful change. The ADCS-CGIC focuses on clinicians' observations of change in the patient's cognitive, functional, and behavioral performance since the beginning of a trial. It relies on both direct examination of the patient and interview of the caregiver. Scored as marked/moderate/minimal improvement or worsening or no change.

  12. Change in the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS CGIC) score. [ Time Frame: Baseline to Week 12 ]
    The ADCS CGIC gives the Clinician's assessment of the patient's response to the treatment. It is intended to be used as a measure of clinically meaningful change. The ADCS-CGIC focuses on clinicians' observations of change in the patient's cognitive, functional, and behavioral performance since the beginning of a trial. It relies on both direct examination of the patient and interview of the caregiver. Scored as marked/moderate/minimal improvement or worsening or no change.


Other Outcome Measures:
  1. Caregiver reported treatment compliance [ Time Frame: 12 weeks ]
    Caregivers will document treatment sessions in a logbook to monitor compliance.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age is greater than or equal to 50 years old
  • Meets the criteria for probable Alzheimer's disease of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)
  • If receiving ongoing cholinesterase inhibitor therapy and/or memantine, must be on a stable dosage for at least the prior 3 months
  • Mini Mental State Examination (MMSE) score between 0-20 at screening assessment
  • Severe Impairment Battery score at baseline of ≤90
  • Outpatient with a reliable caregiver willing to commit to study visits and procedures

Exclusion Criteria:

  • Current psychiatric or other neurologic disease
  • Any history of stroke, seizures, light sensitivity (polymorphous light eruption, solar urticaria, persistent light reactivity) or Lyme disease, including those taking photosensitizing medication
  • Currently undergoing light therapy treatment
  • Increased skin sensitivity at the treatment site including active herpes simplex in the treatment area, history of keloid formation, or history of retinoid use in the past month
  • Pregnant or lactating or planning to become pregnant
  • Any issues with ambulation, vision, or hearing which could, in the opinion of the investigator, interfere with their ability to complete assessments
  • Does not speak English at a level necessary for the completion of the assessments.
  • Has not completed at least a grade eight education, as necessary for the completion of the assessments
  • Currently participating in another clinical research study involving an investigational product.
  • Has participated in a drug or device study within the last 30 days.
  • Any condition, such as agitation/aggression, that in the opinion of the investigator would cause the patient to be unable to comply with study procedures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03328195


Contacts
Contact: Janine Liburd 1-888-730-3805 clinicalstudies@vielight.com

Locations
Canada, Ontario
Chatham Kent Clinical Trials Research Centre Recruiting
Chatham, Ontario, Canada
Contact: Julie Anderson Handsor    5193973791 ext 2910    jandersonhandsor@ckha.on.ca   
The Centre for Memory and Aging Recruiting
Toronto, Ontario, Canada
Contact: Lovelee Cornejo    4166636897 ext 203    lcornejo@memorycentre.ca   
Sponsors and Collaborators
Vielight Inc.

Responsible Party: Vielight Inc.
ClinicalTrials.gov Identifier: NCT03328195     History of Changes
Other Study ID Numbers: P17.02
First Posted: November 1, 2017    Key Record Dates
Last Update Posted: May 7, 2018
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders